Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NG[wN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;IelJiUUN3ME2wMlYyOjN5IN88US=> MkDQV2FPT0WU
H4 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNk[yPEDPxE1? NFXIWWdUSU6JRWK=
PA-1 MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwOEewPVYh|ryP MWjTRW5ITVJ?
NKM-1 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[0T2lEPTB;MT6wOFk{OSEQvF2= NHm3dYhUSU6JRWK=
NEC8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwMkG1O|Ih|ryP NVOzO2NzW0GQR1XS
EoL-1-cell MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jkeGlEPTB;MT6yOlcxOSEQvF2= NEn2OoNUSU6JRWK=
K5 NX\QeIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TJUGlEPTB;MT60NlA4OiEQvF2= M37pcnNCVkeHUh?=
QIMR-WIL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ITWM2OD1zLk[wPFU1KM7:TR?= NHjLVGVUSU6JRWK=
MOLT-16 NEfBPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwN{i2NFQh|ryP M3G1OnNCVkeHUh?=
CHP-212 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fPeGlEPTB;MT64NVM3QSEQvF2= MnqyV2FPT0WU
CTB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwMEKyOFYh|ryP M2f3RXNCVkeHUh?=
MOLT-4 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHXTWM2OD1{LkOyPFU{KM7:TR?= NIfVZ3hUSU6JRWK=
A101D NXvKUmV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn24TWM2OD1{LkO1NFEh|ryP NV33eYRKW0GQR1XS
DOHH-2 NWDzWoJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jQb2lEPTB;Mj60NlI4QSEQvF2= NVfScmZEW0GQR1XS
ES4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrmTWM2OD1{LkSzNVU2KM7:TR?= MX3TRW5ITVJ?
SW780 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwNUC4PFMh|ryP NYTiZ3FTW0GQR1XS
VA-ES-BJ NHy2T2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDlTWM2OD1{LkW0NVEh|ryP NEPS[ohUSU6JRWK=
RPMI-8866 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\jT4dKSzVyPUKuOVYzOTRizszN MVnTRW5ITVJ?
ML-2 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36fFlKSzVyPUKuOVY2PzZizszN NELsO3ZUSU6JRWK=
MSTO-211H MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;DTWM2OD1{LkW3OFUyKM7:TR?= MnzvV2FPT0WU
JVM-3 M4jpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r5dmlEPTB;Mj61PVMzPCEQvF2= M37UUXNCVkeHUh?=
A3-KAW NUfYT2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\xTWM2OD1{Lk[xPFE5KM7:TR?= NF3HTFlUSU6JRWK=
DK-MG MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHHbFdXUUN3ME2yMlYzPDdzIN88US=> MXrTRW5ITVJ?
LNCaP-Clone-FGC M{DuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwNkSzNVgh|ryP MYjTRW5ITVJ?
HT-144 M{DOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwNkS1O|ch|ryP MoL3V2FPT0WU
NB69 NGW1ToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TtUGlEPTB;Mj62OVM{PCEQvF2= MknvV2FPT0WU
A172 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPINlBKSzVyPUKuOlc2QDhizszN NHnSV4dUSU6JRWK=
RS4-11 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLFTWM2OD1{LkeyOFA4KM7:TR?= NEf0d2xUSU6JRWK=
DU-4475 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi2TWM2OD1{Lke5OVAzKM7:TR?= M1LFS3NCVkeHUh?=
SJSA-1 NYr4Z|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\JcWlEPTB;Mj64NlU2PiEQvF2= Mk[zV2FPT0WU
BV-173 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LTdGlEPTB;Mj64OFQ{QSEQvF2= MX7TRW5ITVJ?
U-2-OS NFr2S5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3[WlEPTB;Mj65NVA4KM7:TR?= NGr0Uo5USU6JRWK=
CHP-134 NEm2TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILPbppKSzVyPUKuPVM5QDJizszN MknSV2FPT0WU
D-502MG Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYco9KSzVyPUKuPVcyPTRizszN MoHyV2FPT0WU
KS-1 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTPPGhKUUN3ME2zMlAyPjJ|IN88US=> MknKV2FPT0WU
A204 NIj3UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfyTWM2OD1|LkC1OVg5KM7:TR?= MXHTRW5ITVJ?
KGN M2q2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITaWlRKSzVyPUOuNFg1QTZizszN Mkn2V2FPT0WU
NCI-H292 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj0NJFiUUN3ME2zMlEzODJ6IN88US=> MVvTRW5ITVJ?
CAKI-1 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fvXWlEPTB;Mz6xNlY6PCEQvF2= M1PadnNCVkeHUh?=
C2BBe1 M2m2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnZTWM2OD1|LkG3NFI3KM7:TR?= NWmy[GxbW0GQR1XS
NB10 NUC4WGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT3VHQ2UUN3ME2zMlIxQTZ4IN88US=> M3\vTHNCVkeHUh?=
MHH-NB-11 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW4TW5RUUN3ME2zMlI3QDJ5IN88US=> M1;SdnNCVkeHUh?=
NCI-SNU-1 M4G2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNwMke4OFMh|ryP NV63N|NNW0GQR1XS
HCT-116 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELid2ZKSzVyPUOuN|A{OzVizszN MX;TRW5ITVJ?
G-401 M3S5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv1No9kUUN3ME2zMlM3OzJ{IN88US=> NHzkeGRUSU6JRWK=
MN-60 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LkU2lEPTB;Mz60OFA6OiEQvF2= M{nCdXNCVkeHUh?=
SW982 NWXkTVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwNUC4OFgh|ryP MorJV2FPT0WU
RKO M3LoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz6[WVKSzVyPUOuOVM6OzZizszN MYfTRW5ITVJ?
D-283MED MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v3UmlEPTB;Mz61O|k5PiEQvF2= NWn4bGNYW0GQR1XS
LB996-RCC M3HmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNwNkK1OVgh|ryP MoDaV2FPT0WU
A549 M{PEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H5XGlEPTB;Mz62N|U2OiEQvF2= MnrPV2FPT0WU
LB2241-RCC NI\1[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDzTWM2OD1|Lk[1O|A5KM7:TR?= M4nVb3NCVkeHUh?=
SK-HEP-1 NUHyXJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwN{SyPVch|ryP MoTwV2FPT0WU
G-402 M3Wyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\oeWlEPTB;Mz64NFg{OiEQvF2= NVfNTXM{W0GQR1XS
GOTO M2rBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3U5FKSzVyPUOuPFQ{OzNizszN NYXtdWNIW0GQR1XS
LOXIMVI NYC1cVZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTaTWM2OD1|Lki1Olc2KM7:TR?= NHnYS3BUSU6JRWK=
NH-12 M{DQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwMEG5OVkh|ryP NVHvUVVwW0GQR1XS
CTV-1 M2i4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j3XmlEPTB;ND6wO|k4OyEQvF2= NUHSSY4yW0GQR1XS
CP50-MEL-B MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT4TWM2OD12LkK0N|kzKM7:TR?= NUTaWVhyW0GQR1XS
RH-18 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\WfGlEPTB;ND6yO|cxPiEQvF2= NHu0d4tUSU6JRWK=
NB17 NVrZdWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfITWM2OD12LkOxO|Y5KM7:TR?= NVHTd2VPW0GQR1XS
A375 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3kUW5KSzVyPUSuN|M2OjRizszN MVjTRW5ITVJ?
IST-MES1 NIr2XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX5[ZZIUUN3ME20MlQyPDFzIN88US=> MUTTRW5ITVJ?
MZ2-MEL M4[yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjRW2JIUUN3ME20MlUxOTV3IN88US=> MXPTRW5ITVJ?
CAL-54 NIHaR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\6NGlEPTB;ND61N|AyQSEQvF2= NI\HOJFUSU6JRWK=
NCI-H28 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwNkK3NVch|ryP M{TCNXNCVkeHUh?=
D-247MG Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTqblJKSzVyPUSuO|UxPzJizszN NV\EeYJRW0GQR1XS
NCI-H460 M1\JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULwdFduUUN3ME20MlkyOTJ5IN88US=> NULFWFBjW0GQR1XS
MCF7 NYrkTY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfGTWM2OD13LkS0NlQ1KM7:TR?= NVLkbmlJW0GQR1XS
697 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTVwNES1OUDPxE1? MY\TRW5ITVJ?
ONS-76 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjMTWM2OD13LkW3NFA6KM7:TR?= Ml;rV2FPT0WU
C32 NF:3SXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu4TWM2OD13Lk[wNFI6KM7:TR?= M33pfXNCVkeHUh?=
OS-RC-2 NEXCTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDyXFY3UUN3ME21Mlc{QDh5IN88US=> M4TGV3NCVkeHUh?=
MEL-HO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTXTWM2OD13Lki1OlY4KM7:TR?= MlrkV2FPT0WU
LoVo NYXyVZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LF[mlEPTB;Nj6wNVYzPCEQvF2= M3GxcXNCVkeHUh?=
AGS NGK4do5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7XcYVKSzVyPU[uNVQ5OjhizszN M2Lrd3NCVkeHUh?=
GI-ME-N MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PPfmlEPTB;Nj6yNlQzOSEQvF2= NHOxeWFUSU6JRWK=
H-EMC-SS MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LvVWlEPTB;Nj6zPFYh|ryP M4rVc3NCVkeHUh?=
RVH-421 NHzHd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXadnM3UUN3ME22MlQzPDJ6IN88US=> NYHG[4k4W0GQR1XS
SW954 M1LCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPPTWM2OD14LkW1OVczKM7:TR?= NVjmUJBDW0GQR1XS
NB5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHoZ|VOUUN3ME22MlU3OTh|IN88US=> NWLMVXdDW0GQR1XS
NCI-H2122 NVSxb|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP5UplwUUN3ME22MlU5Pzl|IN88US=> NFjOZ|VUSU6JRWK=
AM-38 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELYZ5VKSzVyPU[uO|U3OzlizszN MmLCV2FPT0WU
KNS-81-FD MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTZwN{[0PVQh|ryP MX7TRW5ITVJ?
LS-513 NFP1bXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTZwN{mwNlYh|ryP MorVV2FPT0WU
A427 NYXq[3Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSxTWM2OD14Lki3PFI6KM7:TR?= Mn\sV2FPT0WU
WM-115 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4foXGlEPTB;Nj65N|I{KM7:TR?= MVfTRW5ITVJ?
COLO-829 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HTXmlEPTB;Nz6yOFE5QCEQvF2= MoPGV2FPT0WU
NCI-H1650 NXvQbo02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DrTGlEPTB;Nz6zPVIzQCEQvF2= M2C4eHNCVkeHUh?=
NCI-H358 M12zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHER|ZKSzVyPUeuOFQ5PzlizszN NV7uS4VkW0GQR1XS
HT-1080 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\4SotKSzVyPUeuOFgzPTRizszN MXLTRW5ITVJ?
HCC2218 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0TWM2OD15Lk[yPVch|ryP NEj3b3pUSU6JRWK=
NCI-H661 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VdXVKSzVyPUeuPFcxPjlizszN MWnTRW5ITVJ?
KM-H2 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX1NYQxUUN3ME23Mlg5Pjl2IN88US=> M3TsdXNCVkeHUh?=
RPMI-2650 M1zrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r1fGlEPTB;Nz65OFQyPCEQvF2= M2HlNnNCVkeHUh?=
NCI-H226 NGfEXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zwO2lEPTB;OD6yNVEzOiEQvF2= M2nLXXNCVkeHUh?=
MKN45 M{TndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvDZlNKSzVyPUiuNlY3ODJizszN MXnTRW5ITVJ?
D-392MG NVfPRXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGwS5FxUUN3ME24MlUzPzJ{IN88US=> MmK2V2FPT0WU
RCC10RGB Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPUTWM2OD16Lki2Olk2KM7:TR?= NYnFfWtMW0GQR1XS
CAL-51 NXzae2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fI[mlEPTB;OT6xNFI2OSEQvF2= NWjlTZVoW0GQR1XS
COLO-678 M1PsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lw[mlEPTB;OT6zNlgyOSEQvF2= MVjTRW5ITVJ?
SK-MEL-24 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnM[5dXUUN3ME25MlU2QDV4IN88US=> NVHWb3d5W0GQR1XS
SK-MEL-30 NUXhXGNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf5V4RKSzVyPUmuPVQ1PzZizszN NWT4PGN7W0GQR1XS
MMAC-SF MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon6TWM2OD1zMD6zPVYyKM7:TR?= Ml;DV2FPT0WU
NTERA-S-cl-D1 NFLETFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfzfXg6UUN3ME2xNE43PTB6IN88US=> MXLTRW5ITVJ?
NB12 NVHtUpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTnXHhQUUN3ME2xNU42ODNizszN M{XyOnNCVkeHUh?=
UACC-257 M33TTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLyfJNNUUN3ME2xNU45Pjl3IN88US=> MnPDV2FPT0WU
LAN-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5SZBKSzVyPUGxMlk6OjhizszN NIm2S|hUSU6JRWK=
SW1573 M4rxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j6PWlEPTB;MUKuN|A5PiEQvF2= NULO[JZ5W0GQR1XS
NMC-G1 NXjBdHYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1cWlEPTB;MUKuOFE4PSEQvF2= M3XRbnNCVkeHUh?=
SHP-77 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLCTWM2OD1zMj61OVc1KM7:TR?= MkDoV2FPT0WU
IGROV-1 NH3MOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF{Lk[1O|Mh|ryP Mnr3V2FPT0WU
22RV1 M3q4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[1c3dKSzVyPUGyMlgxPTlizszN Mk\BV2FPT0WU
SK-MEL-3 M3LPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:4UoZ6UUN3ME2xN{4{QTd|IN88US=> NVjye4VwW0GQR1XS
NCI-H1563 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF|LkSyNFIh|ryP MlPTV2FPT0WU
IGR-1 M4rjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyV3RKSzVyPUG0MlA{PDdizszN MoHUV2FPT0WU
EW-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lo[WlEPTB;MUSuNVY{QSEQvF2= NVLofllYW0GQR1XS
JEG-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj5[XhKSzVyPUG0MlQ6PTNizszN Mn76V2FPT0WU
ES3 NX74UJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHPN|lKSzVyPUG0MlY2PjJizszN NWSwUW4yW0GQR1XS
MDA-MB-175-VII NXHOR|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvhSJBKSzVyPUG0MlcyOTFizszN MmPzV2FPT0WU
P30-OHK NVvGb5FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS3T2lKSzVyPUG1MlA1QTZizszN NEHWNHBUSU6JRWK=
GP5d NWrIeotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSeGlEPTB;MUWuNVQ3PiEQvF2= M4q0bnNCVkeHUh?=
HMV-II M1\PXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzvTWM2OD1zNT6zN|M{KM7:TR?= NVn1cmhvW0GQR1XS
COLO-679 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETBW4hKSzVyPUG1MlUxOSEQvF2= Mo\wV2FPT0WU
JAR MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHQfG1KSzVyPUG1MlczODVizszN NFjaU3FUSU6JRWK=
NCI-H1666 NGL6XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjWTWM2OD1zNT65N|k6KM7:TR?= MY\TRW5ITVJ?
SW48 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrLfJRKSzVyPUG1Mlk2OTZizszN M{judXNCVkeHUh?=
NCI-H720 NIDDTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\NflF1UUN3ME2xOU46QTh7IN88US=> MlrOV2FPT0WU
HT-1197 M2\P[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF4LkCzOVIh|ryP MX7TRW5ITVJ?
HL-60 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknTTWM2OD1zNj6wN|g1KM7:TR?= NWXqNXJlW0GQR1XS
BEN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1viWmlEPTB;MU[uOVY{QCEQvF2= NUX1XFc3W0GQR1XS
HAL-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7zTWM2OD1zNj64PVA6KM7:TR?= NEnv[GVUSU6JRWK=
SW900 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjITWM2OD1zNj65NVMzKM7:TR?= MYfTRW5ITVJ?
SBC-1 M{jUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF5LkW0Nlkh|ryP MWDTRW5ITVJ?
SH-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGwcm9SUUN3ME2xO{42QDRzIN88US=> NETYNpNUSU6JRWK=
UACC-62 M{WyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT1dmlJUUN3ME2xO{44PjN5IN88US=> MWXTRW5ITVJ?
BHT-101 NGPzOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPaTWM2OD1zOT64O|A2KM7:TR?= NHTlXItUSU6JRWK=
DB NWXNXFBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJzLkW2OFkh|ryP M4n0fXNCVkeHUh?=
SK-MEL-1 M2nvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJzLkW4O|Ih|ryP MYPTRW5ITVJ?
NCI-H747 NIqz[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3GXo9KSzVyPUKyMlc{PzlizszN NVvQeHF7W0GQR1XS
SK-LU-1 M4P2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzPepNKSzVyPUKzMlM2OjRizszN MX\TRW5ITVJ?
KG-1 NFPsbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLJ[3pMUUN3ME2yN{41QTR4IN88US=> MUPTRW5ITVJ?
LXF-289 NG\Wb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvmcJZKSzVyPUKzMlcyPCEQvF2= NYf0XZNNW0GQR1XS
HCC1954 NHraRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT5VWVqUUN3ME2yOE45QDR2IN88US=> MoLKV2FPT0WU
Ramos-2G6-4C10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPsSWJKSzVyPUK2MlQ6QDFizszN MYPTRW5ITVJ?
DBTRG-05MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOyNog6UUN3ME2yOk43PDh6IN88US=> NYL5T5dKW0GQR1XS
NCI-H2052 M3rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TrZWlEPTB;MkeuOVY5PCEQvF2= M2DPfXNCVkeHUh?=
RMG-I Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i3dWlEPTB;MkmuOFE{QSEQvF2= NF2yboxUSU6JRWK=
H9 NVf6eIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGThR5RKSzVyPUOxMlMxODhizszN NVH3WnlPW0GQR1XS
GR-ST NH;kU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfiTWM2OD1|Mj60OFU{KM7:TR?= NVLqRoUzW0GQR1XS
Mo-T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj4bXM4UUN3ME2zNk42ODR4IN88US=> NHLPR5RUSU6JRWK=
SW1088 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN{Lkm4NFEh|ryP NVy1RohDW0GQR1XS
LB2518-MEL NHH0dppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml74TWM2OD1|Mz6wO|k4KM7:TR?= M{DNOnNCVkeHUh?=
NCI-H82 NETLeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN|LkG2OlEh|ryP MmLwV2FPT0WU
LAMA-84 NHrWbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz0[41KSzVyPUO0MlYxPzNizszN NFv4VXVUSU6JRWK=
KYSE-450 M4CxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjCNpV4UUN3ME2zOE43Pzd4IN88US=> NHWyZZpUSU6JRWK=
LU-99A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN3LkCwNFch|ryP MXvTRW5ITVJ?
BE-13 M{XI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN3Lk[1OFUh|ryP MVrTRW5ITVJ?
GAK NYL0dXFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPBZnlKSzVyPUO1MlY6PSEQvF2= NUG5WVlVW0GQR1XS
NCI-H1573 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN3Lki4NVgh|ryP NXjwSItXW0GQR1XS
AsPC-1 NXXieZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzRTWM2OD1|Nj6xOVI4KM7:TR?= Ml3BV2FPT0WU
HDLM-2 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi3TohKSzVyPUO2MlMyPiEQvF2= NEjzcmlUSU6JRWK=
NCI-H441 M4jjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN5LkC2PVEh|ryP MUPTRW5ITVJ?
CAL-27 NWLzOYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfvRmZqUUN3ME2zO{44OjNzIN88US=> NIfnUmVUSU6JRWK=
OVCAR-3 M4LXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHCZ|h3UUN3ME2zPU4{OThzIN88US=> NYflNYo5W0GQR1XS
RPMI-8226 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XKNmlEPTB;M{muOVk5KM7:TR?= M3\k[XNCVkeHUh?=
EFO-21 NFvT[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn3dVhpUUN3ME20NE42QDF2IN88US=> MoHFV2FPT0WU
SNU-C2B NWXVc2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jmU2lEPTB;NEGuOVA5PCEQvF2= M{HBSHNCVkeHUh?=
VM-CUB-1 NHT1OllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0TWM2OD12Mz64NFM4KM7:TR?= M3nxTXNCVkeHUh?=
NCI-H2087 NXz1T4dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELPT2RKSzVyPUS1MlAzOzNizszN MWDTRW5ITVJ?
EW-16 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3JVHZKSzVyPUS2MlMyOzdizszN NXu5bXJ6W0GQR1XS
SK-N-AS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC5VW12UUN3ME20Ok44OTZ5IN88US=> MYfTRW5ITVJ?
COR-L105 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\4TWM2OD12Nj64PFU4KM7:TR?= MYrTRW5ITVJ?
DEL NUD2dGpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTR6LkC0Nlkh|ryP NH7rTXhUSU6JRWK=
JVM-2 NX;6c3JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHiTWM2OD12OD6wOVU5KM7:TR?= Ml\nV2FPT0WU
KARPAS-45 M3;PWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrOfZB5UUN3ME20PU41PTN6IN88US=> MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID